Norwich Ventures

Norwich Ventures targets early-stage medical technology companies, providing initial capital in seed and early-stage rounds. The firm states it approaches each investment with a long-term perspective, focusing on companies still proving their initial clinical or technical milestones.

The firm is agnostic about the specific field of medicine. Its portfolio history includes companies in electrophysiology, genomics, and women's health. The common investment criteria are a large unmet medical need, best-in-class technology, and a quick path to proof-of-concept, rather than a specific clinical specialty.

Yes. The firm's website lists six portfolio companies that were acquired, with buyers including Medtronic, Tempus, Qiagen, Laborie, Terumo, and Boston Scientific. These exits span diagnostics and medical devices, consistent with its medtech focus.

The firm does not publicly name its general partners or investment committee members on its website. The team's identities and professional backgrounds are not part of its current public-facing materials, and no recent media profiles or LinkedIn page provide this information.

Based on available information, Norwich Ventures makes direct investments into early-stage medtech companies. There is no public indication that it commits capital as a limited partner to other venture funds, operating instead as a direct, thesis-driven investor.